
    
      The treatment period was followed by a follow-up period starting the day after the last
      intake of study medication, regardless of the actual duration of study drug administration
      and ended on Day 90 (+ 7 days). Participants who did not complete the treatment period also
      entered the follow-up period. It was also possible that participants did not enter the
      follow-up period, e.g. due to withdrawal of consent or termination of study participation.

      Within the US 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.' is sponsor.
    
  